F S&P 500
5,036.00 -71.50 (-1.40%) F Dow Jones
38,206.00 -474.00 (-1.23%) F Nasdaq
17,338.50 -326.00 (-1.85%) E-mini Russell 2000 Index Futur
1,976.70 -30.10 (-1.50%) Petróleo
82.30 -0.51 (-0.62%) Oro
2,326.90 -11.50 (-0.49%)
VBI Vaccines Inc. (VBIV)
Antes de la apertura del mercado:
VBI Vaccines Inc.
160 Second Street
Floor 3
Cambridge, MA 02142
United States
617 830 3031
https://www.vbivaccines.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 131
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Jeffery R. Baxter FCMA | President, CEO & Director | 908.06k | N/D | 1961 |
| Dr. David Evander Anderson | Chief Scientific Officer | 534.25k | N/D | 1970 |
| Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D. | Chief Medical Officer | 544.52k | N/D | 1955 |
| Ms. Nell Beattie | CFO, Head of Corporate Development & Director | N/D | N/D | 1988 |
| Nicole Anderson | Director of Corporate Communications & Investor Relations | N/D | N/D | N/D |
| Ms. Athena Kartsaklis | Senior VP of Finance, Chief Compliance Officer & Principal Financial Officer | N/D | N/D | 1965 |
| Mr. Avi Mazaltov | Global Head of Manufacturing & GM of SciVac | N/D | N/D | 1962 |
| Mr. Misha Nossov | Senior VP of Global Commercial Supply Strategy & Head of Europe | N/D | N/D | N/D |
| Mr. T. Adam Buckley | Senior Vice President of Business Development | N/D | N/D | 1976 |
| Mr. John Robert Dillman | Chief Commercial Officer | N/D | N/D | 1968 |
Descripción
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de VBI Vaccines Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
